Analyst Price Target is $1.75
▲ +154.55% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evofem Biosciences in the last 3 months. The average price target is $1.75, with a high forecast of $2.50 and a low forecast of $1.00. The average price target represents a 154.55% upside from the last price of $0.69.
Current Consensus is
The current consensus among 2 contributing investment analysts is to hold stock in Evofem Biosciences. This rating has held steady since July 2021, when it changed from a Buy consensus rating.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate) a hormone-free vaginal gel and EVO100 an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.